Newsletter Archive

61. 03.27.25 -- How Is The Market Responding To Brisk HPAPI Demand? 3/27/2025
    03/27/25 Bioprocess Online Newsletter
62. 03.26.25 -- De-Risk The Transfer of Process and Product Knowledge With an Experienced CDMO 3/26/2025

    03/26/25 Bioprocess Online Newsletter

63. 03.26.25 -- Revised EU GMP Annex 1: Your Compliance Guide 3/26/2025

    03/26/25 Bioprocess Online Newsletter

64. 03.26.25 -- Intensifying Downstream Processing With Magnetic Separation 3/26/2025
    03/26/25 Bioprocess Online Newsletter
65. 03.25.25 -- How Secure Is Your Cell And Gene Therapy Manufacturing Process? 3/25/2025

    03/25/25 Bioprocess Online Newsletter

66. 03.25.25 -- Expedite Your Process Development With Contract Services 3/25/2025
    03/25/25 Bioprocess Online Newsletter
67. 03.25.25 -- How To Build Resilience Amid Dynamic Biopharma Vendor Relationships 3/25/2025
    03/25/25 Bioprocess Online Newsletter
68. 03.24.25 -- Fast-Track Your Path To Commercialization 3/24/2025

    03/24/25 Bioprocess Online Newsletter

69. 03.24.25 -- Improving Bioprocess Efficiency With New Strategies And Innovations 3/24/2025

    03/24/25 Bioprocess Online Newsletter

70. 03.24.25 -- Host Cell DNA Impurities: A Unique Challenge For rAAV 3/24/2025
    03/24/25 Bioprocess Online Newsletter